Nature Communications (May 2021)
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
- Feng Wang,
- Kiyomi Morita,
- Courtney D. DiNardo,
- Ken Furudate,
- Tomoyuki Tanaka,
- Yuanqing Yan,
- Keyur P. Patel,
- Kyle J. MacBeth,
- Bin Wu,
- Guowen Liu,
- Mark Frattini,
- Jairo A. Matthews,
- Latasha D. Little,
- Curtis Gumbs,
- Xingzhi Song,
- Jianhua Zhang,
- Erika J. Thompson,
- Tapan M. Kadia,
- Guillermo Garcia-Manero,
- Elias Jabbour,
- Farhad Ravandi,
- Kapil N. Bhalla,
- Marina Konopleva,
- Hagop M. Kantarjian,
- P. Andrew Futreal,
- Koichi Takahashi
Affiliations
- Feng Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Kiyomi Morita
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Courtney D. DiNardo
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Ken Furudate
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Tomoyuki Tanaka
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Yuanqing Yan
- Department of Neurosurgery, The University of Texas Health Science Center at Houston
- Keyur P. Patel
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center
- Kyle J. MacBeth
- Celgene Corporation
- Bin Wu
- Agios Pharmaceuticals
- Guowen Liu
- Agios Pharmaceuticals
- Mark Frattini
- Celgene Corporation
- Jairo A. Matthews
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Latasha D. Little
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Curtis Gumbs
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Xingzhi Song
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Jianhua Zhang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Erika J. Thompson
- Department of Genetics, The University of Texas MD Anderson Cancer Center
- Tapan M. Kadia
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Guillermo Garcia-Manero
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Farhad Ravandi
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Kapil N. Bhalla
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Marina Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Hagop M. Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- P. Andrew Futreal
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Koichi Takahashi
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-22874-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
The regulation of resistance to IDH inhibitors in acute myeloid leukaemia is not completely understood. Here the authors reveal with integrative multi-omics analyses that stemness features are major drivers of primary resistance, while high-risk mutations drive acquired resistance.
